G 蛋白偶联受体（GPCRs）是药物研发的重要靶点，但信号转导复杂阻碍了药物开发。研究人员探索了 GPCRs 的偏向性信号传导和细胞内调节剂，发现其在精准医学中具有潜在应用价值，有助于开发更安全有效的药物。 在生命科学和医学领域，药物研发一直是攻克 ...

GPCRs are the targets for around one third of ... “These receptors may not show any effects when knocked out in an animal model,” says Henderson, “but they must have some purpose or they ...

Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few ...

来自中国的研究人员通过激活小胶质细胞Gi-G蛋白偶联受体(Gi-GPCRs)，揭示了该信号通路如何抑制小胶质细胞突触动态、降低神经元活性并破坏神经网络同步化。这项研究为理解健康大脑中Gi-GPCR介导的神经调控机制提供了新见解，对神经科学领域具有重要意义。

“When Heptares formed, we chose to focus on GPCRs because we knew that targeting these receptors leads to drugs,” says Matt Barnes, president and head of R&D at Nxera Pharma. GPCRs are ...

A novel GPS NMR method enabled precise tracking of motions within the β 1-adrenergic GPCR, revealing that the receptor exists in a dynamic equilibrium among inactive, preactive, and active states.

AbbVie and Sosei Heptares will initially focus on developing up to three GPCR-modulating small-molecule drugs to the point at which they are ready to start clinical trials in humans, whereupon ...